Rhino Resource Partners LP (NYSE:RNO) shares decreased -26.25% in last trading session and ended the day at $0.29. RNO Gross Margin is 13.20% and its has a return on assets of -10.40%. Rhino Resource Partners LP (NYSE:RNO) quarterly performance is -71.36%.
Rhino Resource Partners LP (NYSE:RNO) announced that it intends to voluntarily transfer its common units representing limited partner interests of the Partnership (“Common Units”) from the New York Stock Exchange (“NYSE”) to the OTCQB Marketplace (“OTCQB”).
Hooker Furniture Corp. (NASDAQ:HOFT) ended the last trading day at $25.10. Company weekly volatility is calculated as 5.29% and price to cash ratio as 5.48. Hooker Furniture Corp. (NASDAQ:HOFT) showed a weekly performance of -8.96%.
Hooker Furniture (NASDAQ;HOFT) announced that on December 1, 2015, its board of directors declared a quarterly cash dividend of $0.10 per share, payable on December 31, 2015, to shareholders of record at December 15, 2015.
On 14 December, Accuride Corp. (NYSE:ACW) shares decreased -11.52% and was closed at $1.92. ACW EPS growth in last 5 year was 74.30%. Accuride Corp. (NYSE:ACW) year to date (YTD) performance is -55.76%.
On 4 December, Accuride Corporation (NYSE:ACW) announced that global quality organization ASQ has honored Jd Marhevko, Vice President, Quality/Lean Management Systems & EHS for Accuride, with its 2015 Howard Jones Award. The award was presented by ASQ’s Quality Management Division (QMD), a 24,000-member organization to which Marhevko has belonged since 1988. Chair of the ASQ QMD from 2009 to 2011, Marhevko received the award for her “continued dedication to QMD.”
SandRidge Permian Trust (NYSE:PER) shares decreased -14.75% in last trading session and ended the day at $2.37. PER Gross Margin is 96.10% and its has a return on assets of 26.00%. SandRidge Permian Trust (NYSE:PER) quarterly performance is -42.26%.
SandRidge Permian Trust (NYSE:PER) was upgraded by Zacks from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday, AnalystRatings.Net reports.
Global Blood Therapeutics, Inc. (NASDAQ:GBT) caters to the Healthcare space. Its weekly performance is -6.01%. On the last day of trading company shares ended up at $31.89. Global Blood Therapeutics, Inc. (NASDAQ:GBT) distance from 50-day simple moving average (SMA50) is -3.13%.
Global Blood Therapeutics, Inc. (NASDAQ:GBT) announced positive clinical data from the Company’s ongoing Phase 1/2 clinical trial (the GBT440-001 study) in sickle cell disease (SCD) supporting the potential of GBT440, an oral, once-daily therapy, as a mechanism-based and potentially disease-modifying treatment option. Specifically, the data demonstrate that GBT440 inhibits polymerization of sickle hemoglobin, increases hemoglobin concentration, reduces red blood cell damage, improves oxygen delivery, and reduces inflammation.
Leave a Reply